CCR5 Delta 32 Deletion as a Protective Factor in Czech
First-Wave COVID-19 Subjects

J 2021

CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK; Vaclav ADAMEK; Tereza CERVINKOVA et. al.

Základní údaje

Originální název

CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects

Autoři

HUBACEK, Jaroslav A. (203 Česká republika, garant); Ladislav DUŠEK (203 Česká republika, domácí); Ondřej MÁJEK (203 Česká republika, domácí); Vaclav ADAMEK (203 Česká republika); Tereza CERVINKOVA (203 Česká republika); Dana DLOUHA (203 Česká republika); Jozef PAVEL (203 Česká republika) a Vera ADAMKOVA (203 Česká republika)

Vydání

Physiological research, Praha, Fyziologický ústav AV ČR, 2021, 0862-8408

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.139

Kód RIV

RIV/00216224:14110/21:00121769

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.33549/physiolres.934647

UT WoS

000631146600011

EID Scopus

2-s2.0-85103144187

Klíčová slova anglicky

COVID-19; CCR5; Polymorphism; Deletion; Delta 32

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 6. 2021 07:49, Mgr. Tereza Miškechová

Anotace

V originále

Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5 Delta 32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5 Delta 32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5 Delta 32 carriers in SARS-CoV-2-positive/COVID-19-asymptomatic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5 Delta 32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection.

Citovat

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK; Vaclav ADAMEK; Tereza CERVINKOVA; Dana DLOUHA; Jozef PAVEL a Vera ADAMKOVA. CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects. Physiological research. Praha: Fyziologický ústav AV ČR, 2021, roč. 70, č. 1, s. 111-115. ISSN 0862-8408. Dostupné z: https://dx.doi.org/10.33549/physiolres.934647.

@article{1776197,
   author = {Hubacek, Jaroslav A. and Dušek, Ladislav and Májek, Ondřej and Adamek, Vaclav and Cervinkova, Tereza and Dlouha, Dana and Pavel, Jozef and Adamkova, Vera},
   article_location = {Praha},
   article_number = {1},
   doi = {http://dx.doi.org/10.33549/physiolres.934647},
   keywords = {COVID-19; CCR5; Polymorphism; Deletion; Delta 32},
   language = {eng},
   issn = {0862-8408},
   journal = {Physiological research},
   title = {CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects},
   url = {https://www.biomed.cas.cz/physiolres/pdf/2021/70_111.pdf},
   volume = {70},
   year = {2021}
}

TY  - JOUR
ID  - 1776197
AU  - Hubacek, Jaroslav A. - Dušek, Ladislav - Májek, Ondřej - Adamek, Vaclav - Cervinkova, Tereza - Dlouha, Dana - Pavel, Jozef - Adamkova, Vera
PY  - 2021
TI  - CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects
JF  - Physiological research
VL  - 70
IS  - 1
SP  - 111-115
EP  - 111-115
PB  - Fyziologický ústav AV ČR
SN  - 08628408
KW  - COVID-19
KW  - CCR5
KW  - Polymorphism
KW  - Deletion
KW  - Delta 32
UR  - https://www.biomed.cas.cz/physiolres/pdf/2021/70_111.pdf
N2  - Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5 Delta 32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5 Delta 32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5 Delta 32 carriers in SARS-CoV-2-positive/COVID-19-asymptomatic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5 Delta 32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection.
ER  -

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK; Vaclav ADAMEK; Tereza CERVINKOVA; Dana DLOUHA; Jozef PAVEL a Vera ADAMKOVA. CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects. \textit{Physiological research}. Praha: Fyziologický ústav AV ČR, 2021, roč.~70, č.~1, s.~111-115. ISSN~0862-8408. Dostupné z: https://dx.doi.org/10.33549/physiolres.934647.

Přehled o publikaci